Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials. Methods: Studi...
Saved in:
Main Authors: | Frederick Berro Rivera, MD, Sung Whoy Cha, MD, Cruz Linnaeus Louisse, MD, Genquen Philip Carado, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD, Martha Gulati, MD, MS, Byambaa Enkhmaa, MD, PhD, Neha Pagidipati, MD, MPH, Nishant P. Shah, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | JACC: Advances |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772963X24008305 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases
by: Nicola Ferri
Published: (2012-01-01) -
Classification of Acute Coronary Syndrome From a Therapeutic Perspective
by: Cesar Rodrigo Zoni, MD, et al.
Published: (2025-02-01) -
A Randomized Trial of Ionic Silver Dressing to Reduce Surgical Site Infection After Gastrointestinal Surgery
by: Chihiro Kosugi, MD, et al.
Published: (2024-03-01) -
“Doctor, I Want to Be Like This!”: Exploring Global Beauty Body Standards Through a Multicenter Survey
by: Damiano Tambasco, MD, et al.
Published: (2025-01-01) -
The Effect of Intravascular Imaging-Guided Percutaneous Coronary Intervention on Coronary Artery Perforation
by: Yuichi Sawayama, MD, et al.
Published: (2025-01-01)